A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Scientists report CRISPR restores effectiveness of lung cancer treatment on December 17, 2018 at 9:44 am
Christiana Care Scientists Using CRISPR to Target Lung Cancer Credit: Christiana Care Health System The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line ... […]
- Tumor ‘organoids’ may speed cancer treatment on December 17, 2018 at 9:18 am
SAN DIEGO — Collecting cancer cells from patients and growing them into 3-D mini tumors could make it possible to quickly screen large numbers of potential drugs for ultra-rare cancers. Preliminary su... […]
- Researchers develop first ever model for patient-specific treatment of appendix cancer on December 17, 2018 at 9:08 am
Scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM) have recently developed a process that may change the way cancer of the appendix is treated in the future. "There's a ... […]
- Health Union Cancer Survey Highlights Tradeoffs Patients Make Regarding Treatment Decisions on December 17, 2018 at 8:16 am
PHILADELPHIA, Dec. 17, 2018 /PRNewswire/ -- Although cancer treatment can have negative effects on household finances and living expenses, a small percentage of patients considered cost to be a factor ... […]
- Improving CAR T-cell therapy for cancer treatments on December 17, 2018 at 6:50 am
New strategies developed to boost response to CAR T-cell therapy and reduce its toxic side effects. Researchers from the Mayo Clinic (MN, USA) have developed new methods in the hope of improving the c... […]
- BRIEF-Urogen Pharma Initiates Rolling Submission Of New Drug Application For UGN-101 For Treatment Of Low-Grade Upper Tract Urothelial Cancer on December 17, 2018 at 5:38 am
Dec 17 (Reuters) - Urogen Pharma Ltd: * UROGEN PHARMA INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR UGN-101 FOR THE TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG UTUC) * UR... […]
- Durvalumab consolidation treatment cost-effective for non-small cell lung cancer on December 17, 2018 at 5:21 am
Consolidation therapy with durvalumab for patients with stage III non-small cell lung cancer represented a cost-effective use of an expensive immunotherapy, according to study published in JAMA Oncolo... […]
- Third Chincoteague pony dies of swamp cancer; officials trying new treatments on December 17, 2018 at 4:24 am
A Chincoteague pony died of swamp cancer Sunday, the third death from the disease in 2018 and second this month. Lyra had to be put down after battling the mysterious disease longer than any other pon... […]
- ‘The old Kikkan’ gives way to cancer treatment and hair loss on December 16, 2018 at 10:58 am
Weeks before Kikkan Randall felt ready to share her new reality with the public, even some former teammates, she shared it with a customs officer at the U.S.-Canada border. In May, Randall was diagnos... […]
via Bing News